State Street Corp Point Biopharma Global Inc. Transaction History

State Street Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$6.67 - $9.71 $874,323 - $1.27 Million	131,083 Added 3.86%	3,527,235 $23.5 Million
Q2 2023 Aug 14, 2023	BUY	$6.86 - $10.86 $1.88 Million - $2.98 Million	274,757 Added 8.8%	3,396,152 $30.8 Million
Q1 2023 May 15, 2023	SELL	$6.78 - $8.1 $7.9 Million - $9.44 Million	-1,164,862 Reduced 27.18%	3,121,395 $22.7 Million
Q4 2022 Feb 14, 2023	BUY	$5.72 - $9.78 $7.3 Million - $12.5 Million	1,277,089 Added 42.44%	4,286,257 $31.2 Million
Q3 2022 Nov 15, 2022	BUY	$7.24 - $10.31 $5.73 Million - $8.16 Million	791,372 Added 35.68%	3,009,168 $23.3 Million
Q2 2022 Aug 15, 2022	BUY	$5.6 - $9.5 $10.9 Million - $18.5 Million	1,947,859 Added 721.6%	2,217,796 $15.1 Million
Q1 2022 May 16, 2022	BUY	$5.46 - $8.13 $94,157 - $140,201	17,245 Added 6.82%	269,937 $2.15 Million
Q4 2021 Feb 14, 2022	BUY	$4.83 - $9.75 $126,990 - $256,347	26,292 Added 11.61%	252,692 $1.42 Million
Q3 2021 Nov 15, 2021	BUY	$7.42 - $11.26 $1.68 Million - $2.55 Million	226,400 New	226,400 $1.74 Million

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.